Moderna, Inc.
MRNAHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeModerna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The $79.39B market capitalization puts MRNA squarely in large-cap range for its industry. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
Market Cap
$79.39B
Beta
1.09
P/E (TTM)
—
P/E (Fwd)
-43.52
EPS (TTM)
$-7.98
EPS (Fwd)
$-4.57
ROE
-39.0%
ROA
-13.3%
Cash
$5.14B
Total Debt
$1.29B
Free CF
$299.2M
52W Change
645.9%
Annual Financials
Cash vs Debt
Where MRNA stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, MRNA finished 163.60% above its 150-day moving average ($85.85) and 200.01% above its 200-day moving average ($75.43). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MRNA overbought or oversold?
At the October 15, 2026 close, MRNA's RSI(14) was 63.4, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $5.14B in cash comfortably exceeding the $1.29B debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $299.2M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -39.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $18.88B (2022) to $1.92B (2025), a 90% decline worth watching.
With cash comfortably exceeding debt, MRNA has financial flexibility that may help navigate uncertain periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing MRNA.